Everest Organics Limited

Equities

EVERESTO6

INE334C01029

Pharmaceuticals

Market Closed - Bombay S.E. 03:00:42 2024-05-18 am EDT 5-day change 1st Jan Change
137 INR 0.00% Intraday chart for Everest Organics Limited +10.44% +8.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Everest Organics Limited Appoints Abdur Rahman as Company Secretary and Compliance Officer CI
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Everest Organics Limited Announces Resignation of Rekha Singh as Company Secretary and Compliance Officer CI
Everest Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Everest Organics Limited Announces the Demise of Sree Rama Krishna Grandhi, Non-Executive Independent Director CI
Everest Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Everest Organics Limited Declares Dividend for the Financial Year Ended March 31, 2022 CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to B+; Raises Outlook to Stabe MT
Everest Organics Names New Managing Director; Shares Climb 3% MT
Everest Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to BB; Outlook Lowered to Negative MT
Everest Organics Limited Announces the Demise of Dr. Srikakarlapudi Srihari Raju, Managing Director CI
Everest Organics Limited Recommends Dividend for the Financial Year 2021-22 CI
Everest Organics Managing Director Passes Away MT
Everest Organics Limited Announces Demise of Dr. Srikakarlapudi Srihari Raju, Managing Director of the Company CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to BB+; Outlook Stable MT
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Everest Organics Gets Permanent Revocation of Factory Closure Order MT
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Everest Organics : Develops Active Pharmaceutical Ingreditent to Treat COVID-I9 MT
Everest Organics Limited Announces Final Dividend for the Year Ended March 31, 2021 CI
Chart Everest Organics Limited
More charts
Everest Organics Limited is engaged in manufacturing of active pharmaceutical ingredients (API) and their intermediaries. It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole. The Company’s API’s products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5- Thiazolecarboxylate, Ethyl 2-(3-Formyl -4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl -4-Isobutoxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Cyano -4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, and 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride.
More about the company
  1. Stock Market
  2. Equities
  3. EVERESTO6 Stock
  4. News Everest Organics Limited
  5. Everest Organics Gets Permanent Revocation of Factory Closure Order
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW